



SOTAX Group to acquire majority stake in Ortiv-Q3

The SOTAX Group (SOTAX) and Ortiv-Q3 (Ortiv) are pleased to announce their collaboration to further enhance their capabilities in the field of Pharma Services. Through a majority investment into the equity of Ortiv, SOTAX not only strengthens its reach to a major geographic area but also gains access to new technical capabilities and resources that are built-up within Ortiv. Ortiv through this joint venture strengthens its position to grow and perform over average and gains access to the global commercial network of SOTAX.

June 2021: New premises of 10.000 sqft (around 1.000 m2), will be set up in the forthcoming months in Ahmedabad, India, a brand-new, state-of-the-art infrastructure including modern workspace and set of latest instruments to perform cGMP analytical services with a clear focus on complex dosage forms characterization and proof of concept for formulations. The new infrastructure will facilitate accelerating complex formulation development program of global clients and shall work with a high throughput to perform excellent services to our customers.

"With this alliance, SOTAX continues to strengthen its leading position as a complete solution provider in the global market and we are convinced that the adopted strategy will be beneficial for all, our customers, Ortiv as well as SOTAX. We are convinced that this will be a very fruitful collaboration" states Rolf Benz, CEO and President of the Board of SOTAX Group.

"We are convinced that this collaboration will boost the success of Ortiv and will lift the Company to the next level. We see huge potential in the field of Pharma Services especially in the field of complex products in India and with the investment of SOTAX into our company, we are convinced that this will be a success story in the forthcoming years." highlighted Pawan Gupta, Mukesh Kumar and Sadhana Gupta co-founders of Ortiv.

"We are pleased to bring all Ortiv-Q3 employees with their experience and their innovative ideas on board and to further develop the business of our Pharma Services division in order to continue to offer our customers best-in-class services, with an extremely high level of expertise and quality" commented Samir Haddouchi, Managing Director of SOTAX Pharma Services.

Contact:

SOTAX AG
c/o Corporate Marketing
Nordring 1
4147 Aesch
Switzerland

Phone: +41 61 487 54 54
Email: marketing@sotax.com

About SOTAX:

The SOTAX Group is the leading global provider of complete testing solutions for Research and Development (R&D), Quality Control (QC), and In-Process Control (IPC) departments of the pharmaceutical industry. SOTAX's instruments, software, and services are recognized by their customers worldwide as the industry benchmark for best-in-class solutions. It is also the only analytical services supplier specialized in R&D for dissolution and release testing. The company is offering a high level of expertise for complex dosage forms testing as well as an FDA-inspected facility for routine cGMP testing. Its laboratories, located all over the globe, are operating for clients worldwide ranging from virtual companies to big Pharma including generic.

About Ortiv-Q3:

The Ortiv company, founded by enthusiastic and experienced pharma professionals, provides a complete suite of drug release testing for a variety of dosage forms ranging from simple tablets to complex formulations like microspheres, suspensions, emulsions, nano-dispersions, liposomal and topical formulations. Also, Ortiv provides in-vitro permeation studies for topical and solid orals. The company is equipped with innovative and novel tools like microdialysis and oral formulations permeation evaluation system, which can minimize the risk of bio-failures.